A data scientist with no formal biology training used ChatGPT to help design a custom mRNA immunotherapy vaccine for his dog's cancer. The project involved sequencing the tumor to identify neoantigens — mutation-derived proteins that cancer cells express and healthy cells don't — then using the LLM to interpret the output, comb the literature, and work through vaccine design decisions.
The mRNA delivery platform, already validated through COVID-19 vaccines, made the approach tractable. ChatGPT functioned as an on-demand domain expert: explaining variant annotation outputs, helping evaluate peptide binding predictions, and reasoning through which neoantigen candidates were worth pursuing.
Personalized mRNA cancer vaccines are already in clinical trials using the same conceptual pipeline. Moderna's mRNA-4157, co-developed with Merck, reduced recurrence or death risk by 44% against pembrolizumab alone in a Phase 2b melanoma trial. BioNTech has parallel programs running. Both require clinical sequencing infrastructure, oncology teams, and regulatory oversight. None of that applied here.
The <a href="/news/2026-03-14-chatgpt-cancer-vaccine-dog">Hacker News discussion</a> was enthusiastic. One commenter said it made a more convincing case for AI-assisted science than anything the AI companies had managed to produce themselves.
What <a href="/news/2026-03-14-chatgpt-cancer-vaccine-dog">the case</a> illustrates for the LLM space isn't autonomous action — ChatGPT wasn't running sequencing or synthesizing mRNA. It was doing something more specific: collapsing a knowledge barrier that would previously have required years of specialist training. Veterinary treatments carry less regulatory scrutiny than human trials, meaning there was no external check on the accuracy of the bioinformatic pipeline or the neoantigen selection. The data scientist hasn't publicly confirmed whether the vaccine was produced or what effect, if any, it had on his dog.
Moderna's Phase 3 trial for mRNA-4157 is currently enrolling. When it reports, personalized cancer vaccines will have a clear clinical benchmark — and the question of what adequate oversight looks like outside that framework will be harder to sidestep.